Thursday, February 08, 2007
Market News Publishing US - Feb. 08, 2007
By Fain Hughes, firstname.lastname@example.org
SRI International, an independent nonprofit research and development organization, and Telik, Inc. (TELK) announced that they have signed an exclusive license agreement under which SRI will conduct preclinical studies of a Telik drug candidate for the treatment of multiple sclerosis and other autoimmune and inflammatory diseases.
The licensing agreement involves the study of C243, a compound that prevents leukocyte infiltration. Leukocytes are white blood cells that help defend the body against infection. Leukocyte infiltration is strongly linked to tissue injury in chronic autoimmune and inflammatory diseases such as multiple sclerosis, rheumatoid arthritis, and atherosclerosis.
Under the terms of the agreement, SRI will fund and conduct preclinical and toxicology studies directed at supporting an Investigational New Drug (IND) application filing for C243 with the FDA, as well as develop GMP-compliant sources for C243 manufacturing. Telik will have the option to re-acquire C243 rights in the future. In North and South America, Telik has exclusive commercialization rights to C243. Sanwa Kagaku Kenkyusho, Co., Ltd. and Telik share commercialization rights to the compound in Europe, and Sanwa has exclusive commercialization rights in Asia. The license agreement covers territories where Telik has exclusive rights.
KNOBIAS DISCLAIMER: All statements made in this article were made by the Company and do not in any way reflect the opinions of Knobias. Knobias is not a registered broker-dealer, nor investment advisor, and does not endorse or recommend any securities mentioned. This story is provided for informational purposes only and is not intended for trading purposes. Knobias shall not be liable for any actions taken in reliance of any information provided herein. Republication or redistribution of Knobias content is expressly prohibited without prior written consent of Knobias.com, LLC.
ABOUT KNOBIAS: Knobias is a premier financial information provider of trading and investing data covering all U.S. equities for investors and security professionals. Knobias is best described by its three major components: Real-time desktop applications providing quotes, charts, level 2, analysis etc.; Knobias RAiDAR providing thousands of real-time news stories, alerts and documents daily; Knobias fundamentals providing a comprehensive database of fundamental research information.
If your company wishes to participate in the EventX newswire, please contact Knobias: http://www.knobias.com
(c)2007 Market News Publishing Inc. All rights reserved.
Toronto:(416)366-8881 Vancouver:(604)689-1101 Fax:(604)689-1106